Systemic high-dose intravenous methotrexate for central nervous system metastases
Open Access
- 13 December 2005
- journal article
- clinical trial
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 78 (3), 255-260
- https://doi.org/10.1007/s11060-005-9044-6
Abstract
Treatment options for patients with recurrent central nervous system (CNS) metastases are limited. Rapid infusion of high-dose intravenous methotrexate (HD IV MTX) penetrates the blood-brain barrier (BBB) and has reported activity in leptomeningeal metastases. Medical records were reviewed for all patients treated with HD IV MTX (3.5 g/m2) for CNS parenchymal or leptomeningeal metastases. Radiographic response rate, survival, and toxicity were determined. Thirty-one women and one man with a median age of 52 years (range 33–76) were treated with a total of 141 cycles (median 4, range 1–13). Twenty-nine patients had breast cancer, and one each had cancer of unknown primary (CUP), squamous cell carcinoma of the head and neck, and non-small cell lung cancer (NSCLC). An objective radiographic response and stable disease were each observed in nine patients (28%), and 13 (44%) patients progressed. Prior treatment with low-dose MTX for systemic disease did not affect response (P = 0.8). The median overall survival (n = 32) was 19.9 weeks (range 2.9–135.4+) with one patient alive at 135.4 weeks. Myelosuppression and elevated serum hepatic transaminases were the most common acute toxicities (21% and 9% of HD IV MTX cycles, respectively). HD IV MTX is effective in the treatment of CNS metastases with disease control (response or stable) as a best response in 56% of assessable patients. Further study is warranted.Keywords
This publication has 16 references indexed in Scilit:
- The Role of Topotecan in the Treatment of Brain MetastasesThe Oncologist, 2004
- Menopausal Status Dependence of Early Mortality Reduction Due to Diagnosis of Smaller Breast Cancers (T1 v T2-T3): Relevance to ScreeningJournal of Clinical Oncology, 2004
- Complete response of brain metastases originating in breast cancer to capecitabine therapy.2003
- Brain metastasesNeurologic Clinics, 2003
- Leptomeningeal metastases from recurrent squamous cell cancer of the skin.Journal of Neuro-Oncology, 2003
- An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic MeningitisJournal of Neuro-Oncology, 2002
- A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain MetastasesJournal of Neuro-Oncology, 2001
- Ommaya Reservoirs for the Treatment of Leptomeningeal MetastasesNeurosurgery, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Identification of prognostic factors in patients with brain metastases: a review of 1292 patientsInternational Journal of Radiation Oncology*Biology*Physics, 1999